Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer

por Cooper, Alissa J, Kobayashi, Yoshihisa, Kim, Dewey, Clifford, Sarah E, Kravets, Sasha, Dahlberg, Suzanne E, Chambers, Emily S, Li, Jiaqi, Rangachari, Deepa, Nguyen, Tom, Costa, Daniel B, Rabin, Michael S, Wagle, Nikhil, Sholl, Lynette M, Jänne, Pasi A, Oxnard, Geoffrey R
Publicado en Clin Cancer Res (2020)

Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib

por Rosen, Ezra Y., Johnson, Melissa L., Clifford, Sarah E., Somwar, Romel, Kherani, Jennifer F., Son, Jieun, Bertram, Arrien A., Davare, Monika A., Gladstone, Eric, Ivanova, Elena V., Henry, Dahlia N., Kelley, Elaine M., Lin, Mika, Milan, Marina S.D., Nair, Binoj C., Olek, Elizabeth A., Scanlon, Jenna E., Vojnic, Morana, Ebata, Kevin, Hechtman, Jaclyn F., Li, Bob T., Sholl, Lynette M., Taylor, Barry S., Ladanyi, Marc, Jänne, Pasi A., Rothenberg, S. Michael, Drilon, Alexander, Oxnard, Geoffrey R.
Publicado en Clin Cancer Res (2020)